刺
干扰素基因刺激剂
急性呼吸窘迫综合征
炎症
免疫学
TLR4型
目标2
医学
肺
生物
先天免疫系统
免疫系统
炎症体
内科学
工程类
航空航天工程
作者
Yasmine Messaoud‐Nacer,Elodie Culerier,Stéphanie Rose,Isabelle Maillet,Nathalie Rouxel,Sylvain Briault,Bernhard Ryffel,Valérie Quesniaux,Dieudonnée Togbe
标识
DOI:10.1038/s41419-022-04664-5
摘要
Abstract Stimulator of interferon genes (STING) contributes to immune responses against tumors and may control viral infection including SARS-CoV-2 infection. However, activation of the STING pathway by airway silica or smoke exposure leads to cell death, self-dsDNA release, and STING/type I IFN dependent acute lung inflammation/ARDS. The inflammatory response induced by a synthetic non-nucleotide-based diABZI STING agonist, in comparison to the natural cyclic dinucleotide cGAMP, is unknown. A low dose of diABZI (1 µg by endotracheal route for 3 consecutive days) triggered an acute neutrophilic inflammation, disruption of the respiratory barrier, DNA release with NET formation, PANoptosis cell death, and inflammatory cytokines with type I IFN dependent acute lung inflammation. Downstream upregulation of DNA sensors including cGAS, DDX41, IFI204, as well as NLRP3 and AIM2 inflammasomes, suggested a secondary inflammatory response to dsDNA as a danger signal. DNase I treatment, inhibition of NET formation together with an investigation in gene-deficient mice highlighted extracellular DNA and TLR9, but not cGAS, as central to diABZI-induced neutrophilic response. Therefore, activation of acute cell death with DNA release may lead to ARDS which may be modeled by diABZI. These results show that airway targeting by STING activator as a therapeutic strategy for infection may enhance lung inflammation with severe ARDS.
科研通智能强力驱动
Strongly Powered by AbleSci AI